CollPlant (NASDAQ: CLGN), a regenerative medicine company, announced on Friday its financial results for the third quarter ended 30 September 2019.
The company reported revenues for the three months ended 30 September 2019 at USD679,000, up 203% compared to the year-ago period.
The firm posted gross profit for the three months ended 30 September 2019 at USD53,000, down 64% compared to the same period in 2018.
Comprehensive loss for the third quarter of 2019 was USD3.2m, or USD0.69 per share, compared to a comprehensive loss of USD1.3m, or USD0.29 per share, for the third quarter of 2018.
Yehiel Tal, CollPlant's chief executive officer, said, 'Significant developments during the third quarter of 2019 included our progress in the development of a 3D bioprinted implant for the regeneration of breast tissue, and our USD5.5m financing round which included new investors who have deep expertise in 3D printing.'
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development